Heading into 2026, my portfolio allocation leans heavily toward category-defining tech plays that hit the public markets at compelling valuations—well below what they commanded in earlier venture rounds. $CHYM remains a cornerstone position, and for good reason. $ETOR fits the same thesis perfectly. Both are trading significantly below their most recent private funding prices, presenting the kind of timing opportunity that doesn't come around often in this space. ✅